CD8A and neoplasm: Although higher expression of PD-L1, T-cell–inflamed gene expression profile (TcellinfGEP), tumor mutational burden, CD8+ T cells, and stromal tumor-infiltrating lymphocytes have been associated with improved response to pembrolizumab monotherapy in the metastatic setting [19, 20], the association between features of the TME and clinical efficacy with neoadjuvant pembrolizumab are not well understood.